Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management

MM. AlAhmad, S. ZainAlAbdin, K. AlAhmad, I. AlAhmad, S. AbuRuz

. 2023 ; 18 (3) : e0283369. [pub] 20230327

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003745

OBJECTIVES: The study aims to examine the extent to which the updated ACC/AHA management of blood cholesterol guideline (2018) is implemented in practice and to assess the value of the clinical pharmacist interventions in improving physicians' adherence the guidelines recommendations. METHODS: We utilized in this study an interventional before-after design. The study was conducted on 272 adult patients who visited the study site internal medicine clinics and were candidates for statin therapy based on the 2018 ACC/AHA guidelines for cholesterol management. Adherence to guideline recommendations was measured before and after clinical pharmacists' interventions by calculating the percentage of patients receiving statin therapy as per guideline recommendation, the type and intensity (moderate or high intensity) of statin therapy used, and the need for additional non-statin therapy. RESULTS: Adherence with guideline recommendations was significantly improved from 60.3% to 92.6% (X2 = 79.1, p = 0.0001) after clinical pharmacist interventions. Among patients who were on statin therapy, the percentage of those who were on proper statin intensity increased significantly from 47.6% to 94.4% (X2 = 72.5, p = 0.0001). The combination of statins with non-statin therapies such as ezetimibe and PCSK9 inhibitors increased from 8.5% to 30.6% (X2 = 95, p<0.0001) and from 0.0% to 1.6% (X2 = 6, p = 0.014), respectively. The use of other lipid-lowering agents was diminished from 14.6% to 3.2% (X2 = 19.2, p<0.0001). CONCLUSION: Collaboration between physicians and clinical pharmacists is a crucial strategy to improve patients' treatment and hence, achieve better health outcomes among patients suffering from dyslipidemia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003745
003      
CZ-PrNML
005      
20230425140846.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0283369 $2 doi
035    __
$a (PubMed)36972252
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a AlAhmad, Mohammad M $u Department of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, United Arab Emirates $u AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates $1 https://orcid.org/0000000303444056
245    10
$a Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management / $c MM. AlAhmad, S. ZainAlAbdin, K. AlAhmad, I. AlAhmad, S. AbuRuz
520    9_
$a OBJECTIVES: The study aims to examine the extent to which the updated ACC/AHA management of blood cholesterol guideline (2018) is implemented in practice and to assess the value of the clinical pharmacist interventions in improving physicians' adherence the guidelines recommendations. METHODS: We utilized in this study an interventional before-after design. The study was conducted on 272 adult patients who visited the study site internal medicine clinics and were candidates for statin therapy based on the 2018 ACC/AHA guidelines for cholesterol management. Adherence to guideline recommendations was measured before and after clinical pharmacists' interventions by calculating the percentage of patients receiving statin therapy as per guideline recommendation, the type and intensity (moderate or high intensity) of statin therapy used, and the need for additional non-statin therapy. RESULTS: Adherence with guideline recommendations was significantly improved from 60.3% to 92.6% (X2 = 79.1, p = 0.0001) after clinical pharmacist interventions. Among patients who were on statin therapy, the percentage of those who were on proper statin intensity increased significantly from 47.6% to 94.4% (X2 = 72.5, p = 0.0001). The combination of statins with non-statin therapies such as ezetimibe and PCSK9 inhibitors increased from 8.5% to 30.6% (X2 = 95, p<0.0001) and from 0.0% to 1.6% (X2 = 6, p = 0.014), respectively. The use of other lipid-lowering agents was diminished from 14.6% to 3.2% (X2 = 19.2, p<0.0001). CONCLUSION: Collaboration between physicians and clinical pharmacists is a crucial strategy to improve patients' treatment and hence, achieve better health outcomes among patients suffering from dyslipidemia.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a proproteinkonvertasa subtilisin/kexin typu 9 $7 D000071449
650    _2
$a farmaceuti $7 D010595
650    12
$a hypercholesterolemie $x farmakoterapie $x chemicky indukované $7 D006937
650    12
$a kardiovaskulární nemoci $7 D002318
650    _2
$a cholesterol $7 D002784
650    12
$a kardiologie $7 D002309
650    12
$a statiny $x terapeutické užití $7 D019161
650    _2
$a dodržování směrnic $7 D019983
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a časopisecké články $7 D016428
700    1_
$a ZainAlAbdin, Sham $u Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
700    1_
$a AlAhmad, Khozama $u Mediclinic AlAin Hospital, Al Ain, United Arab Emirates
700    1_
$a AlAhmad, Iqbal $u Czech Rehabilitation Hospital, Al Ain, United Arab Emirates
700    1_
$a AbuRuz, Salah $u Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates $u Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, University of Jordan, Amman, Jordan
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 18, č. 3 (2023), s. e0283369
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36972252 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140843 $b ABA008
999    __
$a ok $b bmc $g 1924428 $s 1189954
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c 3 $d e0283369 $e 20230327 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace